Cretostimogene Grenadenorepvec Monotherapy First Results Show 75.7% Complete Response Rate at Any Time in Patients With High-Risk BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer

CG Oncology

related news
Pfizer Ventures gets behind OTR Therapeutics’s $100M series A to boost R&D hub’s capability

Fierce Biotech

December 05 2025
Kailera Therapeutics Announces $600 Million Series B Financing to Further Advance Pipeline of Next-Generation Therapies for the Treatment of Obesity

Kailera

October 14 2025

Get In Touch

Contact Us